Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy-induced peripheral neuropathy.

Terri Armstrong1, Lois Almadrones, Mark R Gilbert

  • 1Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. tsarmstr@mdanderson.org

Oncology Nursing Forum
|March 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.

medRxiv : the preprint server for health sciences·2026
Same author

Inhibition of chemokine CXCL12 modulates the tumor microenvironment in glioblastoma and potentiates immune checkpoint inhibitor efficacy in a tissue-specific manner.

Neuro-oncology advances·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Neuro-oncology advances·2026
Same author

CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas.

Neuro-oncology advances·2026
Same author

Discovery of genetic susceptibility variants in pediatric and adult ependymoma.

Neuro-oncology advances·2026

Chemotherapy-induced peripheral neuropathy is a growing concern, impacting cancer patient quality of life. Improved management strategies and nursing education are crucial for its prevention and treatment.

Area of Science:

  • Oncology Nursing
  • Neuroscience
  • Pharmacology

Background:

  • Peripheral neuropathy is an increasingly recognized dose-limiting toxicity of chemotherapy.
  • Commonly used agents like platinols, vinca alkaloids, and taxanes are associated with this side effect.
  • Management of other chemotherapy toxicities has improved, highlighting neuropathy as a critical concern.

Purpose of the Study:

  • To review the existing literature on chemotherapy-induced peripheral neuropathy (CIPN).
  • To document the scope, current treatment modalities, and prevention strategies for CIPN.
  • To identify gaps in nursing knowledge and education regarding CIPN.

Main Methods:

  • Comprehensive literature review.
  • Inclusion of published abstracts, primary research, and textbook chapters.

Related Experiment Videos

  • Synthesis of data on neuropathy scope, treatment, and prevention.

    • Main Results:

    • Peripheral neuropathy is a significant dose-limiting toxicity for major chemotherapy classes.
    • Improvements in managing other toxicities have amplified the impact of neuropathy.
    • Limited focus on the nervous system in oncology nurse education has been identified.

    Conclusions:

    • Chemotherapy-induced peripheral neuropathy significantly impacts cancer patient quality of life.
    • Effective treatment and prevention of CIPN are essential components of cancer care.
    • Enhanced education and training for oncology nurses are necessary to improve patient care and education regarding CIPN.